Cointime reports: The US Food and Drug Administration has terminated a fast-track drug review program launched in June 2025. FDA leadership told those involved that the National Priority Review Voucher Program will not proceed, though applications remain open and would not advance through the process. HHS spokesperson Emily Hilliard said the pilot is still underway and the FDA is reviewing feedback from a June public hearing to refine its framework.
FDA Halts National Priority Review Voucher Program: Report
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
27m ago
Dow Falls 1% as US Stocks Extend Losses
1h ago
Ondo Finance Joins Singapore MAS Guardian Programme
4h ago
Bitwise Files S-1 for Spot Zcash ETF on Texas Stock Exchange
4h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
4h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
5h ago
Democrats to Probe Trump’s $100B Venezuela Oil Deal